GSTM1 and chronic kidney disease: A clinical trial comparing the efficacy and safety of vadadustat with DA in patients with NDD-CKD and DD-CKD found that vadadustat did not have any clear advantage in maintaining target Hb values and that both study groups had similar safety profiles [75].